Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Cambrex Completes Purchase of Halo Pharma

By Cambrex Corporation | September 13, 2018

Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has completed the acquisition of Halo Pharma, a dosage form Contract Development and Manufacturing Organization (CDMO) located in Whippany, New Jersey and Mirabel, Québec, Canada, for approximately $425 million.

This completes the transaction initially announced on July 23, 2018. The addition of the facilities adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

The newly acquired Cambrex Whippany and Cambrex Mirabel provide formulation development and clinical and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. The facilities’ core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances.

“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combined business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” commented Steve Klosk, president and CEO of Cambrex.

Shawn Cavanagh, COO of Cambrex commented, “This acquisition expands our manufacturing footprint with the addition of two state-of-the art, GMP compliant manufacturing facilities in North America, both with a strong reputation for quality and excellent track records with regulatory approvals from the U.S. FDA, EMEA, DEA, and Health Canada. We look forward to welcoming the 450-person workforce in joining our existing 1,200 experts across the United States and Europe and to continue to build long-term partnerships with our customers.”

(Source: Cambrex Corporation)

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park
Entegris logo
Entegris opens Life Sciences Technology Center in Massachusetts
sustainability
How pharma can optimize for right-the-first-time drug manufacturing and sustainability

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards